Insider Selling: Vaxcyte (NASDAQ:PCVX) CAO Sells 3,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CAO Elvia Cowan sold 3,000 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $60.92, for a total transaction of $182,760.00. Following the completion of the sale, the chief accounting officer directly owned 27,860 shares in the company, valued at approximately $1,697,231.20. This represents a 9.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elvia Cowan also recently made the following trade(s):

• On Monday, October 5th, Elvia Cowan sold 19,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.74, for a total value of $1,648,060.00.

Vaxcyte Trading Up 8.0%

NASDAQ:PCVX traded up $4.87 during trading hours on Wednesday, hitting $65.68. 2,257,729 shares of the company were exchanged, compared to its average volume of 1,640,595. The stock has a market capitalization of $9.77 billion, a price-to-earnings ratio of -8.61 and a beta of 1.31. Vaxcyte, Inc. has a one year low of $39.87 and a one year high of $90.75. The company has a fifty day simple moving average of $61.55 and a 200 day simple moving average of $57.07.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($1.99) EPS for the quarter, beating analysts’ consensus estimates of ($2.11) by $0.12. Equities research analysts predict that Vaxcyte, Inc. will post -7.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on PCVX. Guggenheim increased their target price on shares of Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Cantor Fitzgerald restated an “overweight” rating and issued a $120.00 price target on shares of Vaxcyte in a research report on Monday, October 12th. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. BTIG Research reiterated a “buy” rating and set a $89.00 price objective on shares of Vaxcyte in a research report on Monday, October 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, October 2nd. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.50.

Institutional Investors Weigh In On Vaxcyte

Several institutional investors and hedge funds have recently made changes to their positions in the business. Hsbc Holdings PLC raised its holdings in Vaxcyte by 4.0% during the second quarter. Hsbc Holdings PLC now owns 4,151 shares of the company’s stock worth $241,000 after buying an additional 159 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Vaxcyte by 5.3% in the third quarter. Nisa Investment Advisors LLC now owns 4,189 shares of the company’s stock valued at $238,000 after buying an additional 209 shares in the last quarter. Covestor Ltd lifted its stake in shares of Vaxcyte by 31.1% in the third quarter. Covestor Ltd now owns 939 shares of the company’s stock valued at $53,000 after buying an additional 223 shares in the last quarter. Meeder Advisory Services Inc. grew its holdings in shares of Vaxcyte by 2.9% during the first quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock valued at $484,000 after buying an additional 231 shares during the last quarter. Finally, IFP Advisors Inc increased its position in shares of Vaxcyte by 72.8% during the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock worth $33,000 after acquiring an additional 236 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.